plt101
Epilepsy Intractable
PhytoTech Therapeutics, Ltd.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Epilepsy Intractable cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Clioquinol KU Leuven | Phase 2 | CCC |
Npt 2042 NeuroPro Therapeutics, Inc. | Phase 1 | CCC |
Abi-009 Seattle Children's Hospital | Phase 1 | CC |
Ciprofloxacin Mazandaran University of Medical Sciences | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →